About this work

Purpose
Capturing measured marker values and their trend alongside a structured interpretation gives laboratory-medicine and oncology teams a consistent, complete record of what a result means — tumour markers are poor screening tests, so every result is interpreted in clinical context rather than in isolation — and flags a markedly elevated value or a rising trend on treatment, or a very high AFP or beta-hCG suggesting a germ-cell tumour, for urgent oncology review.
Specification
This form is spec-driven: the living domain spec defines the data model, the four-axis grading engine, and the flag rules, and the same engine grades both the report wizard and the reports dashboard.
Documentation
Aligned with ACB / ACBI tumour-marker guidelines, NICE CG122 (ovarian cancer, CA125) and NICE NG12 (suspected cancer referral), and the ASCO clinical practice guideline on serum tumour markers for germ-cell tumours (AFP, beta-hCG, LDH).